Cadila group receives USFDA approval for Ranolazine Extended-Release


Zydus Cadila has received final USFDA approval to market generic Ranolazine Extended-Release tablets used for treatment of chronic angina in US markets. The company will produce and market the product in the strengths of 500 mg and 1,000 mg.

The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. The tablets will be manufactured at the group’s formulations manufacturing facility at Baddi in Himachal Pradesh.

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.